Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L5KF
|
||||
| Former ID |
DNC008019
|
||||
| Drug Name |
RU-58841
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Acne vulgaris [ICD9: 706.1; ICD10:L70.0] | Discontinued in Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H18F3N3O3
|
||||
| Canonical SMILES |
CC1(C(=O)N(C(=O)N1CCCCO)C2=CC(=C(C=C2)C#N)C(F)(F)F)C
|
||||
| InChI |
1S/C17H18F3N3O3/c1-16(2)14(25)23(15(26)22(16)7-3-4-8-24)12-6-5-11(10-21)13(9-12)17(18,19)20/h5-6,9,24H,3-4,7-8H2,1-2H3
|
||||
| InChIKey |
ARBYGDBJECGMGA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | mRNA of androgen receptor | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Pathways in cancer | |||||
| Prostate cancer | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| AndrogenReceptor Signaling Pathway | |||||
| FSH Signaling Pathway | |||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Coregulation of Androgen receptor activity | |||||
| Regulation of Androgen receptor activity | |||||
| Nongenotropic Androgen signaling | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| FOXA1 transcription factor network | |||||
| Notch-mediated HES/HEY network | |||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Integrated Pancreatic Cancer Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Nuclear Receptors | |||||
| Androgen receptor signaling pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005990) | ||||
| REF 2 | J Med Chem. 2008 Nov 13;51(21):7010-4. Epub 2008 Oct 16.Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.